Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB

Core Insights - Ally Bridge Group NY LLC reduced its stake in Solid Biosciences Inc. by 24.1%, now holding 549,182 shares valued at approximately $3,388,000, representing 2.1% of its investment portfolio [2] - Institutional investors collectively own 81.46% of Solid Biosciences, with several firms increasing their stakes significantly in the second quarter [3] - Insider selling activity includes CFO Kevin Tan and CEO Alexander Cumbo, who sold shares at an average price of $6.44, resulting in ownership decreases of 19.76% and 22.85% respectively [4] Institutional Activity - Bollard Group LLC acquired a new position valued at about $1,761,000 in the second quarter [3] - Geode Capital Management LLC increased its position by 184.5%, now owning 1,510,153 shares worth $7,356,000 after purchasing an additional 979,294 shares [3] - Franklin Resources Inc. raised its stake by 28.9%, owning 1,599,173 shares valued at $7,788,000 after acquiring 358,473 shares [3] Insider Transactions - CFO Kevin Tan sold 26,837 shares for a total of $172,830.28, reducing his ownership to 108,984 shares valued at approximately $701,856.96 [4] - CEO Alexander Cumbo sold 80,258 shares for $516,861.52, leaving him with 270,931 shares valued at around $1,744,795.64 [4] - Over the last three months, insiders sold 597,672 shares valued at $3,816,546, with corporate insiders owning 1.90% of the stock [4] Analyst Ratings - Needham & Company LLC maintains a "buy" rating with a price target of $16.00 [5] - Wedbush reiterates an "outperform" rating with a target price of $14.00 [5] - The average rating for Solid Biosciences is "Moderate Buy" with a price target of $14.70 based on data from MarketBeat [6] Company Overview - Solid Biosciences Inc. is a clinical-stage biotechnology company focused on therapies for Duchenne muscular dystrophy (DMD) [8] - The company's lead investigational therapy, SGT-001, is a micro-dystrophin gene therapy candidate designed to deliver a functional form of the dystrophin gene [9] Stock Performance - Solid Biosciences stock opened at $7.31, with a market cap of $569.52 million and a price-to-earnings ratio of -2.94 [7] - The stock has a 52-week low of $2.41 and a high of $8.72, with a 50-day moving average of $6.24 and a 200-day moving average of $5.73 [7]